Biognosys and Bruker Corporation announced a strategic partnership, in which Bruker has made a majority-ownership investment in the company. Several of Biognosys’ earlier investors have sold their shares to Bruker in a secondary transaction, and Bruker will make new primary investments in Biognosys. Biognosys mass spectrometry-based proteomics solutions help CRO services and proteomics software customers […]
Tags : Nicolas Mosimann
As we have informed here NLS Pharmaceutics, a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announced that it has entered into a definitive agreement with funds managed by BVF Partners, a US fund manager, to raise aggregate gross proceeds […]
Kellerhals Carrard acted as Swiss legal advisor to MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company elevating care with innovative immunology therapeutics, in the closing of its previously announced business combination with Helix Acquisition Corp. (“Helix”), a publicly traded special purpose acquisition company. The business combination was unanimously approved by Helix’s board of directors and was approved […]
Katadyn Group, a Swiss-based specialist in portable water filters and trekking food, has been acquired by a group of entrepreneurs led by Kontivia, a long-term, down-to-earth investment company and invests together with selected entrepreneurial families in established medium- sized companies in Switzerland and southern Germany. The acquisition was consummated through Bifolia Holding which was renamed in Katadyn Group following the closing of the transaction. The majority shareholder of Katadyn Holding, Adrian Schmassmann, and […]
Helix Acquisition Corp, a Nasdaq-listed special purpose acquisition company and MoonLake Immunotherapeutics, a Swiss based clinical-stage biotechnology company focused on creating next-level therapies for inflammatory skin and joint diseases agreed on a business combination. At closing of the envisaged business combination, MoonLake will have access to approximately USD 230 million in cash (subject to redemptions), […]
MoonLake Immunotherapeutics, a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory skin and joint diseaseshas closed a Series A financing round, lead by BVF Partners LP. Other investors included Merck KGaA, Darmstadt, Germany. MoonLake Immunotherapeutics was established by an international team of immunology specialists to create next-level therapies for inflammatory skin and joint […]
The Kellerhals Carrard Startup Desk acted as legal counsel to Qnami, a Quantum Tech startup, in closing its Series A Financing Round raising a total of CHF 4 million. Led by the Venture Capital Funds Runa Capital and SIT Capital and further supported by seed investors Quantonation, ZKB, Verve Ventures and High Tech Gründerfond. Kellerhals […]
Kellerhals Carrard, under the responsibility of partners Claudia Götz Staehelin (pictured), Oliver M. Brupbacher and Nicolas Mosimann, advised Moderna on legal and regulatory aspects related to the establishment of its supply chain for its COVID-19 Vaccine and Swiss launch preparations, including trade compliance and regulatory aspects.
The team was led by partner Nicolas Mosimann (Corporate/M&A - pictured) and comprised associates Sophie Holdt, Sarah Schneider (both Corporate/M&A), Samuel Rickli (Notary), Melanie Huber and Larissa Simeon (both Employment).